Ark Funds Buy $8.7 Million of Tempus AI After 14% Weekly Drop

1 articles · Updated · TheStreet · Jul 23

188,785 Tempus AI shares were added by Cathie Wood’s Ark funds on July 20, a roughly $8.7 million purchase after the healthcare AI stock fell 14% in five trading days.
The selloff followed Tempus AI’s $1.5 billion all-stock-heavy deal for Personalis, which will add minimal residual disease cancer-testing capabilities but raised investor concerns about dilution.
Tempus shares are now down 22% year to date and nearly 56% from their $104.32 peak in October 2025, even after first-quarter results beat expectations and fiscal 2026 revenue guidance was lifted to $1.59 billion-$1.6 billion.
Wood has kept buying Tempus since its June 2024 IPO and now holds it as ARKK’s No. 2 position at 4.89%, reflecting her broader view that AI-led healthcare is a major long-term growth theme.
That conviction comes as Ark’s flagship fund trails the market this year—down 4.87% versus the S&P 500’s 8.26% gain—and has seen about $1.42 billion in net outflows over the past 12 months.